AzTrials
AzTrials

Small Bowel ObstructionSBONCT06101719

Use of a Water Soluble Contrast-Based Protocol to Assist in the Management of Pediatric Adhesive Small Bowel Obstruction

An observational study of Small Bowel Obstruction and Contrast Media Adverse Reaction, run by Children's Hospital Colorado at 9 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this prospective observational study is to evaluate the diagnostic and therapeutic utility of an enteral contrast challenge for pediatric patients with adhesive small bowel obstruction (ASBO). The aims are to 1. Determine if an enteral contrast challenge is safe in the evaluation of children with ASBO 2. Read more about this study

Who is it for?
Ages 1 year to 20 years
What is being tested?
Enteral contrast challenge
How many people
136 participants
Where
9 sitesUnited States
Study dates
1 Oct 2020to 31 Dec 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year to 20 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: Children with adhesive small bowel obstruction admitted to one of 9 participating sites and underwent a trial of non operative management

Who may be able to join

  • children 1-20 years
  • diagnosed with an adhesive small bowel obstruction by an attending pediatric surgeon
  • underwent a trial of nonoperative management on hospital admission

Who cannot join

  • peritonitis
  • suspicion of incarcerated or internal hernia
  • active intra-abdominal malignancy
  • inflammatory bowel disease
  • less than four weeks since most recent abdominal operations
  • pneumatosis
  • pneumoperitoneum
  • known contrast allergy

Trial locations and contacts

9 sites in 1 country.

9 sites in 1 country

United States9 sites
  • Children's Hospital Colorado

    Aurora, Colorado, 80045

  • Children's Medical Center of Dallas

    Dallas, Texas, 75390

  • Children's Hospital Los Angeles

    Los Angeles, California, 90027

  • UCSF Benioff Children's Hospital

    Oakland, California, 94609

  • Phoenix Children's Hospital

    Phoenix, Arizona, 85006

  • Oregon Health Sciences University

    Portland, Oregon, 97239

  • Primary Children's Hospital

    Salt Lake City, Utah, 84113

  • Rady Children's Hospital

    San Diego, California, 92123

  • Seattle Children's Hospital

    Seattle, Washington, 98105

Other trials in United States

About this study

The goal of this prospective observational study is to evaluate the diagnostic and therapeutic utility of an enteral contrast challenge for pediatric patients with adhesive small bowel obstruction (ASBO). The aims are to

  1. Determine if an enteral contrast challenge is safe in the evaluation of children with ASBO
  2. Determine if an enteral contrast challenge decreases the need for operation among children with ASBO Children with ASBO who are cared for at one of 9 participating sites who undergo a trial of non operative management will be observed. Comparisons will be made between those who receive and enteral contrast challenge and those who do not. Outcomes to be evaluated include adverse events related to the contrast, rate of operative intervention, and hospital length of stay.
Read the detailed description

Study Design and Patient Population The investigators conducted a prospective observational study at nine children's hospitals that are members of the Western Pediatric Surgery Research Consortium. IRB approval was obtained from each site with waiver of consent for enrollment. Enrollment took place between 2020-2022. Inclusion criteria were children 1-20 years diagnosed with an ASBO by an attending pediatric surgeon and underwent a trial of nonoperative management (NOM) on hospital admission. The use of an enteral contrast protocol was at the discretion of the attending surgeon. Exclusion criteria included peritonitis, suspicion of incarcerated or internal hernia, active intra-abdominal malignancy, inflammatory bowel disease, <4 weeks since the most recent abdominal operation, pneumatosis, pneumoperitoneum, or known contrast allergy. If the attending surgeon made the decision to take a child directly to the operating room (OR) with no attempt at NOM, these children were excluded. Children under one year of age were excluded as the rate of successful NOM is lower in this age group.

Site details and Contrast Protocols At the start of the study, four of the nine sites had a contrast protocol in place for ASBO diagnosis and management. During the course of the study, contrast protocols were developed and implemented at each of the five additional sites. At study initiation, three sites used contrast routinely, one used it selectively and 5 did not use contrast. At study conclusion, five sites used contrast routinely and four used it selectively.

Contrast agent, volume of contrast, and contrast dilution were not standardized across sites due to the differences in hospital specific formularies; otherwise, the protocol was standardized across sites. Diatrizoate meglumine (osmolality of 1940 mOsm/kg) was used preferentially at eight sites and Ioversol (702 mOms/kg) at one site. Patients received 30-200ml (based on age or weight depending on site) of enteral contrast followed by X-rays at 8-12 hours and 24 hours after contrast administration. Patients were included in the contrast arm if enteral contrast, administered as part of an abdominal CT scan, was followed with subsequent x-rays to assess for progression of contrast to the colon. Failure (complete bowel obstruction) was defined as failure of contrast having not reached the colon by 24 hours after oral administration at which point operative intervention was recommended. The decision to operate was at the discretion of the attending surgeon.

Sample Size Calculation The study was powered to detect a 15% difference in operative rate between the contrast and no contrast groups based on the adult literature. To detect this difference with 80% power, the investigators aimed to enroll 314 patients.

Data Collection and Outcomes Study data were collected and managed using the Research Electronic Data Capture (REDCap) software tool hosted at the University of Colorado. REDCap is a secure, web-based application designed to support data capture for research studies. The surgical inpatient census was monitored daily by study personnel at each site for patients with ASBO. Once identified, data were collected based on a review of the electronic medical record at each site 30 days following hospital discharge. Data collected included patient demographics, medical and surgical history, clinical presentation, laboratory studies, and imaging, management approach including type, volume, dilution of any contrast agent used. Complications specific to the contrast administration including allergic reaction, aspiration of contrast, cardiac arrhythmia, and renal failure were recorded. Details of the hospital course including length of stay, need for operation, indications for operation, and subsequent postoperative course and complications were also included.

Statistical Analysis Descriptive statistics were summarized for continuous variables with medians and interquartile ranges, and for categorical variables with frequencies and percentages. Group differences were tested via t-test or Kruskal-Wallis test for continuous variables and Chi-Squared test or Fisher's Exact test for categorical variables. Comparisons were made between those who received contrast and those who did not. Logistic regression was used to assess the association between contrast and need for operation adjusting for age, body mass index for age z-score (or weight for height z-score for patients under 24 months of age per Centers for Disease Control and Prevention standards), volume of contrast administered, and number of previous laparotomies (< 3 v. ≥3). A subset analysis was performed among patients who received enteral contrast. Comparisons were made based on type of contrast agent used and final osmolality of contrast administered. Additional comparisons were made between only those patients who were successfully managed nonoperatively and then between those patients who required abdominal operation, based on contrast status.

Being tested
Enteral contrast challenge
Keywords
Pediatric adhesive small bowel obstruction, enteral contrast challenge

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Enteral contrast challengeDiagnostic test

    Contrast agent, volume of contrast, and contrast dilution were not standardized across sites due to the differences in hospital specific formularies; otherwise, the protocol was standardized across sites. Diatrizoate meglumine (osmolality of 1940 mOsm/kg) was used preferentially at eight sites and Ioversol (702 mOms/kg) at one site. Patients received 30-200ml (based on age or weight depending on site) of enteral contrast followed by X-rays at 8-12 hours and 24 hours after contrast administration.

Study groups in NCT06101719
Study groupRoleWhat they receive
Contrast GroupInclusion criteria: children 1-20 years diagnosed with an adhesive small bowel obstruction by an attending pediatric surgeon and underwent a trial of nonoperative management (NOM) on hospital admission and received an enteral contrast challenge. Exclusion criteria included peritonitis, suspicion of incarcerated or internal hernia, active intra-abdominal malignancy, inflammatory bowel disease, <4 weeks since the most recent abdominal operation,45 pneumatosis, pneumoperitoneum, or known contrast allergy. If the attending surgeon made the decision to take a child directly to the operating room (OR) with no attempt at NOM, these children were excluded. Children under one year of age were excluded as the rate of successful NOM is lower in this age group
Receives: Diagnostic Test: Enteral contrast challenge
No Contrast groupInclusion criteria: children 1-20 years diagnosed with an adhesive small bowel obstruction by an attending pediatric surgeon and underwent a trial of nonoperative management (NOM) on hospital admission and who did not receive an enteral contrast challenge. Exclusion criteria included peritonitis, suspicion of incarcerated or internal hernia, active intra-abdominal malignancy, inflammatory bowel disease, <4 weeks since the most recent abdominal operation, pneumatosis, pneumoperitoneum, or known contrast allergy. If the attending surgeon made the decision to take a child directly to the operating room (OR) with no attempt at NOM, these children were excluded. Children under one year of age were excluded as the rate of successful NOM is lower in this age group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of patients who required an operation

    operative lysis of adhesions performed due to failure of non operative management

    Measured: 1 year

Secondary outcomes (2)
  1. Total hospital length of stay in days

    total hospital length of stay among patients successfully managed non operatively

    Measured: 1 year

  2. Adverse events resulting from contrast administration

    adverse events related to contrast administration

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Oct 2023
  2. Study start1 Oct 2020
  3. Primary completion31 Dec 2022
  4. Study completion31 Dec 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
136 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06101719
Sponsor's protocol ID
20-2538
Acronym
SBO
Status last verified
Aug 2024
First submitted
17 Oct 2023
Last updated
23 Aug 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Small Bowel Obstruction and Contrast Media Adverse Reaction, run by Children's Hospital Colorado at 9 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 9 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of patients who required an operation (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Aug 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in